Archive - October 2018
Gilead raises outlook despite dip in revenue
Lundbeck schizophrenia drug fails Phase III trial
Medical and Scientific Excellence Awards: There’s still time to enter!
Alexion targets RNAi with $637m Dicerna deal
Keytruda hits survival targets in first-line kidney cancer
Bayer preps filings for new prostate cancer drug
FCB’s new offering, Huntsworth Health buys Navience and Cuttsy+Cuttsy launch e-book
Using High-Throughput Automation to Accelerate Biologic Drug Formulation